|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results suggest a possible association of SNP rs8099917 with higher odds of chronic HCV infection but do not indicate a putative influence of the investigated SNPs on the sustained virologic response.
|
24678513 |
2014 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results of treatment response showed that CC (major) genotype of IFNL3 (rs12979860) and TT (major) genotype of IFNL3 (rs8099917) are associated with the likelihood of achieving a higher sustained virological response (SVR), to combined daclatasvir and sofosbuvir therapy, in genotype 3-infected HCV patients, whereas the individuals with TT (minor) genotype of IFNL3 (rs12979860) and GG (minor) genotype of IFNL3 (rs8099917) are more susceptible to chronic HCV infection and treatment relapse, suggesting a role of IFNL3 (rs12979860) and (rs8099917) in the treatment outcome of combined daclatasvir and sofosbuvir therapy in chronic HCV genotype 3 infection.
|
30431653 |
2019 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The purpose of the study was to establish methods for determining the SNP rs8099917 associated with IL28B, which might be useful for further research of the treatment of HCV.
|
21529139 |
2011 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The presence of a Y93H variant was associated with higher HCV RNA levels and TT genotype at rs8099917 of IL28B.
|
25904097 |
2016 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The multivariate logistic analysis subsequently identified apoB-100 (odds ratio (OR), 1.602; 95% confidence interval (CI), 1.046-2.456), alpha-fetoprotein (OR, 0.764; 95% CI, 0.610-0.958), non-wild-type ISDR (OR, 5.617; 95% CI, 1.274-24.754), and the rs8099917 major genotype (OR, 34.188; 95% CI, 10.225-114.308) as independent factors affecting rapid initial virological response (decline in HCV RNA levels by ≥3-log10 at week 4).
|
23918536 |
2013 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The most significant positive factors affecting the SC HCV included IL-28B single nucleotide polymorphism (SNP) rs12979860 (CC) and SNP rs8099917 (TT) (OR 4.03, p<0.001) and (OR 3.14, p<0.002), female gender (OR 2.72, p<0.001), young age (OR 2.30, p<0.008), and past history of jaundice (OR 5.12, p<0.001).
|
31060998 |
2019 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The method constitutes a simple and reliable assay, which may be readily available for genotyping of rs12979860 and rs8099917 in laboratories that support hepatitis C treatment centers.
|
22664181 |
2012 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The major alleles of IL28B (rs12980275 A, rs11881222 A, rs8099917 T, and rs7248668 G) are associated with increased odds of liver disease severity in HIV patients infected with HCV-genotype 3.
|
23103287 |
2013 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
the Interferon lambda (IFNL) polymorphisms genotypes (rs8099917, rs12979860 and rs12980275) and the presence of mutations in HCV core protein were analyzed in 59 patients with HCC, and also in 50 cirrhotic patients (without HCC).
|
27035616 |
2016 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The impact of IL-28B in Asian patients with different viral genotypes remains elusive.We try to elucidate the effect of IL-28B genetic variants in a large Asian cohort with different viral genotypes.The association between the IL-28B rs8099917 genotype and liver fibrosis was investigated in 1288 patients with biopsy-proven CHC.Patients with hepatitis C virus genotype 1 (HCV-1) infection comprised 59.4% of the population.
|
29517696 |
2018 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The IL28B rs8099917 genotypes were determined among 100 HCV-infected patients and the viral load was also estimated.
|
30988680 |
2019 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The IL13 rs20541 T allele and IL28B rs8099917 GG genotype are negative predictors of survival in patients on RRT, while the IL28B rs12979860 TT genotype increases the risk of death only in patients negative for HBV or HCV infection.
|
26039912 |
2015 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The IL-28B rs12979860 CC and rs8099917 TT genotypes were proved to be predictor for pegylated-interferon (PEG-IFN)/ribavirin (RBV)-treated hepatitis C virus (HCV) patients.
|
25769643 |
2015 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The higher allele frequency of rs12979860 C and rs8099917 T observed in non-HCV-infected individuals may indicate a potential protective role for these IL28B-related polymorphisms.
|
24259970 |
2013 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The goal of this study was to examine whether an IL28B polymorphism (rs8099917) is associated with natural clearance of HCV and with disease parameters of HCV infection in an HCV hyperendemic area of Japan.
|
25100136 |
2014 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The dominant HCV sequences classified by the response were subjected to systematic sliding-window comparison analysis to characterize response-specific viral sequences, along with IL28B SNP analyses (rs8099917).
|
22577043 |
2012 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The association of rs12979860 and rs8099917 single nucleotide polymorphisms (SNPs) near IL28B with sustained virological response (SVR) in hepatic allograft recipients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV) for recurrent hepatitis C virus (HCV) infection remains inconclusive.
|
25225180 |
2014 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The allelic discrimination assay by Taqman real-time PCR was developed to determine genotypes of SNPs, rs12979860 and rs8099917, which were analyzed in 65 Korean patients with HCV genotype-1.
|
21907615 |
2011 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of this study was to investigate whether the SNP of IL28B (rs8099917) and amino acid substitutions in the NS5A region in patients with HCV genotype 2 affect the response to IFN and ribavirin combination therapy.
|
24995561 |
2015 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of this study was to determine whether a single IL-28B genotype SNP rs8099917 or rs12979860 determination is sufficient to predict treatment failure in patients with chronic HCV.
|
21900787 |
2011 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of this study is to investigate whether this IL-28B SNP (rs8099917) and specific missense mutations in the HCV core region affect the response to IFN therapy for HCV genotype 3a.
|
25907669 |
2015 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of our research was to clarify study whether IL-28B gene polymorphism (rs8099917) is associated with HTLV-1/HCV co-infection.
|
22336134 |
2012 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The rs8099917 genotype and total PEG-IFN dose were associated with SVR in patients with hepatitis C virus genotype 1.
|
22156487 |
2011 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The rs8099917 TT genotype is significantly independently predictive of RVR, which is the single best predictor of SVR, in Asian HCV-2 patients.
|
21254157 |
2011 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The association was observed in HCV mono-infected (OR, 2.49; 95% CI, 1.64-3.79; P = 1.96 x 10(-5)) and HCV/HIV coinfected individuals (OR, 2.16; 95% CI, 1.47-3.18; P = 8.24 x 10(-5)). rs8099917 was also associated with failure to respond to therapy (OR, 5.19; 95% CI, 2.90-9.30; P = 3.11 x 10(-8)), with the strongest effects in patients with HCV genotype 1 or 4.
|
20060832 |
2010 |